Is Conexeu Sciences going out of business?

CONEXEU SCIENCES INC. (CNXU) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

CONEXEU SCIENCES INC. (CNXU) fundamentals, assembled from SEC filings.

Five questions, kept separate

Survival - Critical

Runway cannot be estimated from the available cash and cash-flow fields. Adjusted shares outstanding increased 123.9% over the comparison year.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Evidence incomplete

The current price is available, but the filing does not contain enough applicable valuation evidence to interpret it.

Event risk - Evidence unavailable

No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

• Shares dilution YoY: 123.93% (YoY)
• Interest coverage: -2051.6x
• Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-06-15.

Price as of 2026-09-07.